Faeth Therapeutics, Inc.
FTH
$32.34
$3.7913.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -53.30% | 606.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -89.23% | 3,342.14% | |||
| Operating Income | 89.23% | -3,342.14% | |||
| Income Before Tax | 90.60% | -3,508.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 90.60% | -3,508.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 90.60% | -3,508.99% | |||
| EBIT | 89.23% | -3,342.14% | |||
| EBITDA | 89.24% | -3,365.31% | |||
| EPS Basic | 97.84% | -3,415.11% | |||
| Normalized Basic EPS | 97.84% | -3,319.43% | |||
| EPS Diluted | 97.84% | -3,415.11% | |||
| Normalized Diluted EPS | 97.84% | -3,319.43% | |||
| Average Basic Shares Outstanding | 335.73% | 2.67% | |||
| Average Diluted Shares Outstanding | 335.73% | 2.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||